New York City’s housing shortage may find an unlikely hero in its glut of underused office buildings. A new report released Thursday by Comptroller Brad Lander estimates that the first major wave of ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

The portfolio strategy team at Goldman Sachs ranks the 11 sectors in the S&P 500 index by absolute and relative ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

While no vision loss was noted, researchers observed slight corneal thickening and decreased endothelial cell count, ...

Serum levels of C1M, a biochemical marker of type I collagen degradation, may predict progression of total joint damage in ...

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy, and I am delighted to welcome him to the Protalix ...

Global companies have been hit with a brutal $320 billion in lost profit since 2017, and it has nothing to do with bad ...

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...